EGFR and non-small cell lung carcinoma: Importantly, ARID1A alterations have been associated with shorter PFS among patients with tyrosine kinase inhibitor (TKI)‐sensitive EGFR‐mutated NSCLC treated with first‐generation EGFR inhibitors [43].